Effects of Hydrodilatation With Corticosteroid Injection and Biomechanical Properties in Patients With Adhesive Capsulitis After Breast Cancer Surgery

Chang Won Lee, MD1, In Soo Kim, MD2, Jeong-Gil Kim, MD, MPH1, Hyeoncheol Hwang, MD3, Il Young Jung, MD4, Shi-Uk Lee, MD, PhD5, Kwan-Sik Seo, MD, PhD1

1Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul; 2Department of Rehabilitation Medicine, Seosong Hospital, Incheon; 3Department of Rehabilitation, Hallym University Dongtan Sacred Heart Hospital, Hwaseong; 4Department of Rehabilitation Medicine, Chungnam National University Sejong Hospital, Sejong; 5Department of Rehabilitation Medicine, Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Korea

Objective To compare the biomechanical properties of the glenohumeral joint capsule between adhesive capsulitis (AC) after breast cancer surgery and idiopathic AC and demonstrate the effects of hydrodilatation (HD) with corticosteroid injection for AC after breast cancer surgery.

Methods Twenty-three prospective patients with AC after breast cancer surgery (BC group) and 44 retrospective patients with idiopathic AC without breast cancer (CON group) underwent HD with corticosteroid injection and home exercise training. We compared their biomechanical characteristics (capsular capacity, maximal pressure, and capsular stiffness). In the BC group, the passive range of motion (ROM) of the affected shoulder and a questionnaire (Shoulder Pain and Disability Index [SPADI]) were evaluated at baseline and 2 and 4 weeks after treatment.

Results The BC group showed higher biomechanical characteristics (maximal pressure and capsular stiffness) than did the CON group. The mean maximal pressure and capsular stiffness were 519.67±120.90 mmHg and 19.69±10.58 mmHg/mL in the BC group and 424.78±104.42 mmHg and 11.55±7.77 mmHg/mL in the CON group (p=0.002 and p=0.001, respectively). And, the BC group showed significant improvements in all ROMs (abduction, flexion, and external rotation) and the SPADI pain and disability sub-scores following the treatment.

Conclusion The glenohumeral joint capsular stiffness was greater in the patients with AC after breast cancer surgery than in those with idiopathic AC. HD with corticosteroid injection was effective in treating AC after breast cancer surgery.

Keywords Breast Neoplasms, Adhesive capsulitis, Hydrodilatation, Capsular distention, Shoulder joint
INTRODUCTION

Adhesive capsulitis (AC), often referred to as frozen shoulder, is one of the most common causes of upper-extremity pain. Its etiology includes various diseases, such as long-term immobilization, advanced age, surgical treatment, trauma, diabetes mellitus, herniated disc, and stroke [1]. Synovial inflammation and subsequent reactive capsular fibrosis of the glenohumeral joint capsule are known pathophysiological mechanisms of AC [2,3].

Physical therapy, anti-inflammatory drugs, oral steroids, hydrodilatation (HD), and intra-articular corticosteroid injections are common treatments for AC [4]. Combining HD with corticosteroid therapy, in which steroids and a sufficient amount of isotonic sodium chloride solution are injected into the glenohumeral joint capsule, has been reported to improve the range of motion (ROM) of the shoulder and reduce pain and inflammation [5,6]. As a result, HD with corticosteroid injection is one of the treatment regimens often used in patients with AC.

AC is a common complication of breast cancer surgery, especially in patients who undergo axillary lymph node dissection [7-9]. Despite advances in less invasive and more selective surgical procedures for breast cancer, many disorders causing upper-extremity dysfunction and pain, such as AC, occur even after surgery [7,10]. Previous studies have reported that the prevalence of AC between 13 and 18 months post-breast cancer surgery was 10.3% [11] and increased to 22.2% until 5 years after surgery in Asian patients with breast cancer [12].

Although the exact pathophysiology of AC after breast cancer surgery is unknown, it may be affected by the surgery itself, postoperative shoulder movement restrictions, lymphedema, and radiation therapy [7]. However, since it is conventionally accepted that there is no fundamental difference from other mechanisms, the treatment method proceeds in the same manner as idiopathic AC [8].

To our knowledge, no published research has reported whether HD with corticosteroid injection has an effect on AC after breast cancer surgery or whether the pathological condition is similar to idiopathic AC. Advances in real-time pressure-volume monitoring techniques for HD have provided information on the biomechanical properties of the glenohumeral joint capsules related to AC [13,14] and hemiplegic shoulder pain [15].

This study aimed to evaluate the effects of HD with corticosteroid injection on the passive ROM and pain and disability scores of the shoulder affected with AC after breast cancer surgery and identify the biomechanical properties of the glenohumeral joint capsule.

MATERIALS AND METHODS

Breast cancer surgery group (BC group)

A total of 24 consecutive patients were prospectively enrolled in this study (Fig. 1). The enrolled patients were diagnosed with AC after breast cancer surgery and scheduled for HD. The Institutional Review Board of Seoul National University Hospital approved this study (No. 1606-137-774), and all participants provided written informed consent in conformance with the ethical standards of the Declaration of Helsinki.

AC was defined as an insidious painful condition with limited shoulder ROM in at least two directions. The limited ROM in each direction of the shoulder was <30° for external rotation, <130° for flexion, and <80° for abduction on goniometric measurements [13,15]. Patients were excluded when they had any systemic or structural disorders that could result in limited ROM or pain, such as major trauma, shoulder surgical history, rotator cuff tear, or inflammatory joint disease. Male patients and patients with stage IV breast cancer were also excluded. The sample size was determined via consultation with the Medical Research Collaborating Center at the hospital.

Fig. 1. The study design for the prospective (patients with AC after breast cancer surgery) and retrospective groups (patients with idiopathic AC) that underwent ultrasound-guided IHD is presented. AC, adhesive capsulitis; IHD, intra-articular hydrodilatation.
Idiopathic AC group (CON group)

The CON group consisted of patients who were diagnosed with AC and received HD for the first time (Fig. 1). This group had the same inclusion and exclusion criteria as the BC group but did not include any patients with breast cancer. The participants in the CON group completed baseline clinical and biomechanical assessments on their first visit, and their data were analyzed with no additional follow-up.

ROM and SPADI in the BC group

Clinical and sonographic evaluations were performed to assess patient eligibility prior to HD. Passive shoulder ROM was measured using a long-arm goniometer while the patients were sitting on a stool. Shoulder abduction was assessed in the coronal plane, with the shoulder externally rotated. Forward flexion was measured in the sagittal plane, with the hands pronated. External rotation was measured in the transverse plane, with the shoulder adducted and the elbow flexed at 90° [16]. The measured ranges of abduction, flexion, and external rotation were summed and used for the analysis of treatment progress [17].

The Shoulder Pain and Disability Index (SPADI) is a self-report questionnaire that can be administered in an outpatient setting and has been used in many patients with shoulder diseases, including AC [18]. It consists of 13 questions in two domains: pain (five items) and disability (eight items) to evaluate shoulder pathology-related pain and disability. Each question is scored on a visual analog scale ranging from 0 to 10, where 0 indicates no difficulty/no pain and 10 indicates most difficult/worst pain. Each item in both domains is assigned the same weight and eventually changed to a score ranging from 0 to 100. Herein, the prospective participants underwent baseline ROM assessment, clinical survey (SPADI), ultrasonography, and HD-related biomechanical assessment on their first visit and follow-up ROM assessment and clinical survey (SPADI) at 2 and 4 weeks after the procedure.

The BC group was further subdivided into breast-conserving surgery (BCS) and radical mastectomy (RM) groups according to the surgical method, and the difference between these subgroups was evaluated.

Biomechanical properties of the BC and CON groups

Intra-articular HD of the shoulder to evaluate the biomechanical properties of the glenohumeral joint capsules was performed following the standard protocol reported in previous studies [13-15]. Initially, the participants sat on a chair with a pronated forearm on the thigh. They were asked to remain sufficiently relaxed to avoid changing the intra-articular pressure of the affected shoulder. After skin disinfection, a 22-gauge spinal needle was inserted into the posterior intra-articular space under ultrasound guidance (Accuvix V20; Medison, Seoul, Korea) and then connected to the pressure-monitored HD system. This machine is designed for constant volume-speed fluid infusion and simultaneous intra-articular pressure monitoring [13-15]. The injectate consisted of a total of 50 mL mixture including 1 mL (40 mg) triamcinolone, 10 mL 1% lidocaine, and 39 mL isotonic sodium chloride solution. The fluid was infused at a rate of 7 mL per minute. When the examiner observed that the pressure was too high or the participants felt much pain, the infusion was stopped temporarily until the intra-articular pressure and pain stabilized. The fluid infusion was terminated when the intra-articular pressure increased to 800 mmHg, the pressure-volume profiles reached the third phase, or the patients requested to terminate the procedure because of excessive pain or discomfort. This procedure generated typical pressure-time curves. One patient in the BC group (n=24) and one patient in the CON group (n=45) stopped the procedure because of severe pain and vasovagal symptoms, respectively (Fig. 1).

Because the fluid was injected at a constant rate (7 mL per minute), it was easy to convert to a pressure-time curve. The pressure-time curve generally consists of three phases: initial filling phase (first), elastic deformation phase (second), and plastic deformation phase (third). The slope of the second phase is thought to be caused by stiffness of the shoulder joint capsule ($S_{cap}$). The capsular pressure at the maximal volume ($P_{max}$) and capsular capacity ($V_{max}$, total infused volume) were also recorded as biomechanical parameters of the shoulder joint capsules [14] (Fig. 2).

All patients received brochures on shoulder home exercises for AC and were educated on stretching exercises once before HD [19]. They were instructed to continue their daily home exercises after the procedure.

Statistical analysis

All statistical analyses were performed using the SPSS software version 26.0 (IBM, Armonk, NY, USA). We com-
pared the demographic factors (age, height, weight, duration of symptoms, involved side, diabetes mellitus, and surgical method) and biomechanical parameters ($V_{max}$, $P_{max}$, and $S_{cap}$) between the two groups using an independent t-test or the Mann-Whitney test, depending on normal distribution satisfaction. Within-group analysis was performed using paired t-tests when the difference between the baseline and follow-up test results was normally distributed. The Wilcoxon signed-rank test was performed when the results were not normally distributed. Statistical significance was defined as a p-value of <0.05.

We also compared the SPADI score (pain sub-score, disability sub-score, and total score) and ROM (flexion, abduction, external rotation, and total ROM) before HD and at 2 and 4 weeks after the procedure in the BC group. For the three timelines, analysis of variance or the Kruskal-Wallis test (when the assumptions of parametric statistical analysis were not satisfied) was used. The values that differed between the three points were analyzed using Bonferroni correction, and statistical significance was defined as a p-value of <0.017.

RESULTS

Demographic characteristics of the BC and CON groups

There were no significant differences between the two groups, except for age. The mean patient age was 51.30±6.58 years in the BC group and 57.38±8.63 years in the CON group (p=0.005). The mean height was 158.67±5.10 cm in the BC group and 158.69±7.43 cm in the CON group (p=0.986). The mean weight was 56.87±5.29 kg in the BC group and 59.76±8.75 kg in the CON group. The mean duration of symptoms was 7.63±5.51 months in the BC group and 11.26±12.24 months in the CON group. The right side was involved in 15 patients (65.2%) in the BC group and 34 patients (80.9%) in the CON group. Four patients (17.4%) in the BC group and six patients (14.3%) in the CON group had diabetes mellitus. In the BC group, 10 (43.5%) and 13 (56.5%) patients underwent BCS and RM, respectively (Table 1).

Biomechanical properties of the BC and CON groups

Among the biomechanical parameters, the $P_{max}$ and $S_{cap}$ were significantly different between the two groups (Table 2). The $P_{max}$ (519.67±120.90 mmHg; p=0.002) and $S_{cap}$ (19.69±10.58 mmHg/mL; p=0.001) were significantly higher in the BC group than in the CON group. There was no significant difference in the $V_{max}$ between the two groups. All three biomechanical features showed no significant difference between the BCS and RM subgroups divided according to the type of surgery within the prospective BC group (Table 2).

Changes in the ROM and SPADI disability and impairment scores in the BC group

Significant changes were observed in the post-treatment ROM and SPADI scores. All ROM (abduction, flexion, external rotation, and total ROM) and SPADI scores (pain, disability, and total score) significantly improved (Table 3, Fig. 3). The total ROM was 214.67°±48.48° be-
fore HD and 286.23°±50.98° and 311.87°±37.74° at 2 and 4 weeks after HD, respectively. As shown in Table 3, the greatest improvement in all ROM was observed between the initial and post-2-week evaluations (p<0.017). Although the mean ROM increased between weeks 2 and 4, the difference was not significant.

In the BC group, both BCS and RM subgroups showed significant improvements in all ROM and SPADI scores at 2 and 4 weeks after HD compared with the baseline values. In the within-group analysis of the effect of the shoulder ROM, both subgroups showed significant improvements at 2 and 4 weeks after HD. However, there was no significant difference in any of the ROM between 2 and 4 weeks after HD. In the comparison of the shoulder ROM changes between the BCS and RM subgroups, no significant difference was identified in all ROM at baseline and 2 weeks after HD. However, at 4 weeks post-HD, the ranges of shoulder flexion and external rotation and total ROM in the BCS group were significantly greater than those in the RM group (Table 3).

Significant results were also observed in the SPADI score changes. After the intervention, there was a significant decrease in both pain and disability sub-scores, as shown in Fig. 3 (p<0.001). Twenty-one patients (91.3%) presented with decreased pain and disability sub-scores; however, there was no improvement or slight deterioration in two patients. The greatest improvement in all SPADI scores was seen between the initial and 2-week follow-up evaluations, and no significant differences were found between the 2- and 4-week follow-up evaluations, similar to the ROM results (Table 3, Fig. 3).

Although the within-group changes confirmed significant improvements in both pain and disability sub-scores after the intervention, no significant change between the 2- and 4-week post-HD evaluations was observed. The pain and disability sub-scores and total SPADI score did

| Table 1. Demographic characteristics of the BC and CON groups |
|---------------------------------|------------------|------------------|------------------|
| Characteristic                  | BC group (Prospective, n=23) | CON group (Retrospective, n=44) | p-value          |
| Age (yr)                        | 51.30±6.58        | 57.38±8.63       | 0.005**          |
| Height (cm)                     | 158.67±5.10       | 158.69±7.43      | 0.986            |
| Weight (kg)                     | 56.87±5.29        | 59.76±8.75       | 0.153            |
| Duration of symptoms (mo)       | 7.63±5.51         | 11.26±12.24      | 0.183            |
| Involved side, right (%)        | 15 (65.2)         | 34 (80.9)        | 0.248            |
| Diabetes mellitus (%)           | 4 (17.4)          | 6 (14.3)         | 0.364            |

| Type of surgery                 | BCS | RM  |
|---------------------------------|-----|-----|
|                                 | 10  | 13  |

Values are presented as mean±standard deviation. BC, breast cancer surgery; CON, idiopathic adhesive capsulitis; BCS, breast-conserving surgery; RM, radical mastectomy.

**p<0.01 using an independent t-test.

| Table 2. Biomechanical properties of the BC and CON groups |
|----------------------------------------------------------|
| Properties of the glenohumeral capsule                   |
|----------------------------------------------------------|
| BC group (prospective)                                   |
| Total (n=23)                                             |
| Vmax (mL)                                               | 37.77±12.26 | 38.40±14.35 | 0.836 |
| Pmax (mmHg)                                             | 519.67±120.90 | 500.88±121.18 | 0.953 |
| Scap (mmHg/mL)                                          | 19.69±10.58 | 19.48±13.47 | 0.937 |
| BC group (prospective)                                   |
| BCS (n=10)                                              |
| RM (n=13)                                               |
| p-value                                                 |
| Total (n=44)                                            |
| p-value                                                 |
| Vmax (mL)                                               | 38.96±11.80 | 0.700 |
| Pmax (mmHg)                                             | 424.78±104.42 | 0.002** |
| Scap (mmHg/mL)                                          | 11.55±7.77 | 0.001** |

Values are presented as mean±standard deviation. BC, breast cancer surgery; CON, idiopathic adhesive capsulitis; BCS, breast-conserving surgery; RM, radical mastectomy; Vmax, maximal infused volume; Pmax, capsular pressure at the maximal volume; Scap, capsular stiffness.

**p<0.01 using an independent t-test between the BC (total) and CON groups.
Table 3. Shoulder ROM and SPADI score in the BC group (total, BCS, and RM subgroups)

|                  | Initial                  | 2 weeks after HD  | 4 weeks after HD |
|------------------|--------------------------|-------------------|------------------|
|                  | Total (n=23)   BCS (n=10) | RM (n=13) p-value | Total (n=23)   BCS (n=10) | RM (n=13) p-value | Total (n=23)   BCS (n=10) | RM (n=13) p-value |
| **ROM (°)**      |                          |                   |                  |
| Abduction        | 57.80±18.59 58.00±22.62  | 57.64±15.79 0.965 | 84.06±24.46 89.20±29.56  | 80.10±20.06 0.148 | 96.67±26.21 101.33±18.38  | 93.56±16.92 0.343 |
| p-value          | - - - - 0.000<sup>a</sup> | - - - - 0.000<sup>a</sup> | - - - - 0.000<sup>a</sup> |
| Flexion          | 129.65±29.82 125.40±30.81 | 132.92±29.85 0.561 | 153.48±22.73 161.80±18.51  | 147.08±24.24 0.126 | 162.15±16.81 172.00±7.56  | 155.58±18.28 0.014<sup>*</sup> |
| p-value          | - - - - 0.000<sup>a</sup> | - - - - 0.000<sup>a</sup> | - - - - 0.002<sup>a</sup> |
| External rotation| 27.22±18.48 32.70±21.45  | 23.00±15.37 0.220 | 48.70±21.91 57.50±18.48  | 41.92±19.64 0.091 | 53.05±20.35 61.00±22.63  | 47.75±17.68 0.031<sup>*</sup> |
| p-value          | - - - - 0.000<sup>a</sup> | - - - - 0.002<sup>a</sup> | - - - - 0.004<sup>b</sup> |
| Total ROM        | 214.67±48.48 216.10±55.88  | 213.56±44.31 0.904 | 286.23±50.98 308.50±55.57  | 269.10±41.44 0.065 | 311.87±37.74 334.33±34.32 296.89±33.15 0.025<sup>a</sup> |
| p-value          | - - - - 0.000<sup>a</sup> | - - - - 0.005<sup>a</sup> | - - - - 0.011<sup>a</sup> |
| **SPADI (/100)** |                          |                   |                  |
| Total score      | 49.25±18.03 51.92±20.66  | 47.21±16.30 0.548 | 24.00±14.08 24.23±11.72  | 23.84±16.15 0.950 | 23.27±13.06 23.29±12.45  | 23.26±13.96 0.996 |
| p-value          | - - - - 0.000<sup>a</sup> | - - - - 0.005<sup>a</sup> | - - - - 0.000<sup>a</sup> |

Values are presented as mean±standard deviation.

ROM, range of motion; SPADI, shoulder pain and disability index; BC, breast cancer surgery; BCS, breast-conserving surgery; RM, radical mastectomy; HD, hydrodilatation.

<sup>a</sup>Significant difference from the previous within-group evaluation.

<sup>b</sup>Significant difference between the initial and 4-week follow-up within-group evaluations.

<sup>*</sup>p<0.05 using Student t-test or the Mann-Whitney test between the BCS and RM subgroups.
not significantly differ between the subgroups (Fig. 3, Table 3).

**DISCUSSION**

This study examined the effects of HD with corticosteroid injection on the passive shoulder ROM and SPADI pain and disability sub-scores in patients with AC after breast cancer surgery. During this study, all 23 patients showed improvements in the shoulder ROM, and most of them (91.3%) showed an improvement in pain and disability. Several previous studies have reported improvements in the ROM after intra-articular injection in patients with idiopathic AC [20-22]. In a recent study, HD with corticosteroid injection was suggested to be more effective in relieving pain and improving limited ROM for frozen shoulder than intra-articular or subacromial steroid injection [23]. In addition to the effect of corticosteroids, HD is thought to be responsible for treating AC through extrinsic and intrinsic factors [24]. The mechanical effect of capsular distention through a large injection volume causes the release of the joint by expanding the volume capacity and decreasing the tendency of intra-articular pressure [17]. Another intrinsic mechanism of joint distention is that it reduces the condition of increased glycosaminoglycan concentration and myofibroblast activity in patients with AC [25]. Piotte et al. [20] reported that the passive shoulder ROM improved by 18.6° for abduction, 17.2° for flexion, and 24.4° for external rotation 3 weeks after the first HD. In our study, the ROM at 2 weeks after HD changed by 26.26° for abduction, 23.83° for flexion, and 21.48° for external rotation, with statistical significance. In addition, the average ROM changes between the baseline and 2-week follow-up evaluations and between the 2- and 4-week follow-up evaluations were calculated as 32.56° for abduction, 28.16° for flexion, and 23.65° for external rotation. The range of external rotation improved to a similar extent; however, the ranges of abduction and flexion showed greater improvements herein than in the study by Piotte et al. [20]. Although a direct comparison was difficult because of the differentiation between the ROM measurement methods (e.g., patient position) and the HD procedure technique, our study suggests that the effects of HD with corticosteroid injection on ROM improvement in patients with AC after breast cancer surgery are similar to or greater than the effects on ROM improvement in patients with idiopathic AC.

Obvious improvements in the ROM were observed in the first 2 weeks after treatment. The patients were instructed to perform home exercise programs for 4 weeks; however, there was no significant improvement in the ROM between the 2- and 4-week follow-up evaluations. In an earlier study, intra-articular corticosteroid injection was more effective in improving shoulder disability and pain in patients with AC than supervised physiotherapy [26]. Another study stated that physiotherapy following joint distension had a positive effect on the active ROM of the shoulder, but yielded no effect on the pain, function, and quality of life (QOL) of patients with AC [27].
our study, a home exercise program was utilized without monitoring instead of supervised physical therapy; therefore, patient compliance might have been low. This might be the reason for the lack of significant changes in the shoulder ROM between the 2- and 4-week follow-up evaluations.

A significant decrease in the SPADI pain and disability sub-scores was also observed in the first 2 weeks. As with the improvement in the ROM, this is also thought to be an effect of HD with corticosteroid injection rather than the home exercises. The minimal clinically important difference (MCID) in the SPADI score generally ranges from 8 to 13 [28]. The average outcomes of the changes in the SPADI score were 31.42 for pain and 22.08 for disability. Therefore, the improvements in the SPADI scores were clinically meaningful because the decreases were greater than the MCID in the study. However, the degree of decline in the SPADI scores was not as much as that reported in a previous study that showed an average decrease of 44.4 for pain and 36.8 for disability at 3 weeks [20]. Therefore, our study suggests that the ROM improvement in the patients with AC after breast cancer surgery was superior to that in the patients with idiopathic AC; however, the effects on the SPADI score did not seem to have improved as much as we expected in the patients with AC after breast cancer surgery. This is because various upper-extremity problems can occur after breast cancer surgery [7,10]. For example, in addition to AC, lymphedema, pectoralis tightness, and myofascial pain syndrome can affect shoulder pain, disability, and QOL among patients.

The distinctive properties of the glenohumeral joint capsules are a higher \( P_{\text{max}} \) at a lower \( V_{\text{max}} \) and stiffer \( S_{\text{cap}} \) in patients with idiopathic AC than those in healthy individuals among previous studies [13,14]. In this study, the BC group showed a higher \( P_{\text{max}} \) at a similar \( V_{\text{max}} \) and a higher \( S_{\text{cap}} \) than did the CON group. Because other indicators (\( P_{\text{max}} \) and \( V_{\text{max}} \)) are partially affected by capsule-preserving HD, the \( S_{\text{cap}} \) is known to be the most accurate parameter of capsular stiffness [15]. Therefore, our study suggests that patients with AC after breast cancer surgery have stiffer capsules than those with idiopathic AC. Factors affecting capsular stiffness can be divided into problems of the capsule itself and those of the surrounding soft tissues, including the ligamentous structures. Postoperative restriction of the shoulder [29], postoperative inflammatory conditions, soft tissue tightness due to radiotherapy [30], and pectoralis tightness [10] are all possible mechanisms that can explain why patients with AC after breast cancer surgery have stiffer capsules than those with idiopathic AC.

In our study, the BCS and RM subgroups showed no significant difference in the biomechanical properties at baseline and all shoulder ROM and SPADI scores at follow-up, except for the ranges of flexion and external rotation and the total ROM at 4 weeks post-HD. At that point, the greater degree of ROM recovery in the BCS group than in the RM group is consistent with the previous finding that the limitation of shoulder ROM was more prominent in patients who underwent mastectomy than in those who underwent BCS [31]. However, these ROM differences resulting from the different types of surgery did not change the pain or disability sub-scores probably because complications other than AC also affect patients [7].

Further studies on this problem are needed to explore the underlying pathophysiological mechanism of AC after breast cancer surgery; the results could be used to establish a finer therapeutic intervention.

This study has several limitations. First, this study was a comparative study of retrospective data for characterizing biomechanical properties. Initially, we attempted to perform propensity score matching. However, owing to the small number of patients who met the inclusion criteria, it was impossible to perform such, resulting in a difference in the mean age. Second, knowing the exact effect of HD with corticosteroid injection is impossible because there was no control group utilized for comparison. However, there have been many previous studies on the effect of HD with corticosteroid treatment on idiopathic AC, and they have reported that HD is one of the most effective methods for managing frozen shoulder [5,6,20-24]. In comparison with these studies, our study found that HD with corticosteroid injection was also effective in treating AC after breast cancer surgery. Nonetheless, the absence of a prospective control group in this study remains a limitation because of the inability to analyze the relationship between shoulder joint capsular stiffness and the treatment progress with HD for AC.

In conclusion, this study demonstrated that HD with corticosteroid injection helped reduce shoulder ROM limitations, pain, and disability in the patients with AC after breast cancer surgery. We also revealed that the
stiffness of the glenohumeral joint capsule in the patients who underwent breast cancer surgery and were diagnosed with AC was greater than that in the patients who were diagnosed with idiopathic AC. Further studies are needed to discover the exact pathophysiological mechanisms involved among patients with AC after breast cancer surgery and detailed treatment options for stiffer shoulder capsules.

CONFLICT OF INTEREST

One of the authors of this manuscript is an editor of Annals of Rehabilitation Medicine. The author did not engage in any part of the review and decision-making process for this manuscript.

ACKNOWLEDGMENTS

This work was supported by a Korea Medical Device Development Fund grant funded by the Korean government (Ministry of Science and ICT; Ministry of Trade, Industry and Energy; Ministry of Health and Welfare; and Ministry of Food and Drug Safety) (Project No. 9991006938, KMDF_PR_20200901_0273).

AUTHOR CONTRIBUTIONS

Conceptualization: Seo KS, Lee SU, Kim IS. Methodology: Lee CW, Kim IS, Kim JG. Formal analysis: Lee CW, Kim IS, Hwang H, Jung IY. Funding acquisition: Seo KS. Project administration: Seo KS, Lee SU, Kim IS. Visualization: Lee CW Kim IS. Writing — original draft: Lee CW, Kim IS, Seo KS. Writing — review and editing: All authors. Approval of the final manuscript: All authors.

REFERENCES

1. Pearsall AW, Speer KP. Frozen shoulder syndrome: diagnostic and treatment strategies in the primary care setting. Med Sci Sports Exerc 1998;30(4 Suppl):S33-9.
2. Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. Clin Orthop Relat Res 2000;(372):95-109.
3. Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. J Bone Joint Surg Br 2007;89:928-32.
4. Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med 2010;38:2346-56.
5. Bell S, Coghlan J, Richardson M. Hydrodilatation in the management of shoulder capsulitis. Australas Radiol 2003;47:247-51.
6. Buchbinder R, Green S, Forbes A, Hall S, Lawler G. Arthrographic joint distension with saline and steroid improves function and reduces pain in patients with painful stiff shoulder: results of a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2004;63:302-9.
7. Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. Arch Phys Med Rehabil 2006;87(3 Suppl 1):S96-9.
8. Cheville AL, Tchou J. Barriers to rehabilitation following surgery for primary breast cancer. J Surg Oncol 2007;95:409-18.
9. Leidenius M, Leivonen M, Vironen J, von Smitten K. The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005;92:23-31.
10. Yang EJ, Park WB, Seo KS, Kim SW, Heo CY, Lim JY. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. J Surg Oncol 2010;101:84-91.
11. Yang S, Park DH, Ahn SH, Kim J, Lee JW, Han JY, et al. Prevalence and risk factors of adhesive capsulitis of the shoulder after breast cancer treatment. Support Care Cancer 2017;25:1317-22.
12. Wong CJ, Tay MRJ, Aw HZ. Prevalence and risk factors of adhesive capsulitis in Asian breast cancer patients undergoing an outpatient community cancer rehabilitation program. Arch Phys Med Rehabil 2021;102:843-8.
13. Chung SG, Lee KJ, Kim HC, Seo KS, Lee YT. Intra-articular pressure profiles of painful stiff shoulders compared with those of other conditions. PM R 2009;1:297-307.
14. Lee KJ, Lee HD, Chung SG. Real-time pressure monitoring of intraarticular hydraulic distension for painful stiff shoulders. J Orthop Res 2008;26:965-70.
15. Yi Y, Lee KJ, Kim W, Oh BM, Chung SG. Biomechanical properties of the glenohumeral joint capsule in...
hemiplegic shoulder pain. Clin Biomech (Bristol, Avon) 2013;28:873-8.
16. Guler-Uysal F, Kozanoglu E. Comparison of the early response to two methods of rehabilitation in adhesive capsulitis. Swiss Med Wkly 2004;134:353-8.
17. Koh ES, Chung SG, Kim TU, Kim HC. Changes in biomechanical properties of glenohumeral joint capsules with adhesive capsulitis by repeated capsule-preserving hydraulic distensions with saline solution and corticosteroid. PM R 2012;4:976-84.
18. Roach KE, Budiman-Mak E, Songsiridej N, Lerratanakul Y. Development of a shoulder pain and disability index. Arthritis Care Res 1991;4:143-9.
19. Griggs SM, Ahn A, Green A. Idiopathic adhesive capsulitis: a prospective functional outcome study of nonoperative treatment. J Bone Joint Surg Am 2000;82:1398-407.
20. Piotte F, Gravel D, Moffet H, Fliszar E, Roy A, Nadeau S, et al. Effects of repeated distension arthrographies combined with a home exercise program among adults with idiopathic adhesive capsulitis of the shoulder. Am J Phys Med Rehabil 2004;83:537-46.
21. Jacobs LG, Barton MA, Wallace WA, Ferrousis J, Dunn NA, Bossingham DH. Intra-articular distension and steroids in the management of capsulitis of the shoulder. BMJ 1991;302:1498-501.
22. Gam AN, Schydlowsky P, Rossel I, Remvig L, Jensen EM. Treatment of “frozen shoulder” with distension and glucocorticoid compared with glucocorticoid alone: a randomised controlled trial. Scand J Rheumatol 1998;27:425-30.
23. Ladermann A, Piotton S, Abrassart S, Mazzolari A, Ibrahim M, Stirling P. Hydrodilatation with corticosteroids is the most effective conservative management for frozen shoulder. Knee Surg Sports Traumatol Arthrosc 2021;29:2553-63.
24. Rymaruk S, Peach C. Indications for hydrodilatation for frozen shoulder. EFORT Open Rev 2017;2:462-8.
25. Price FM, Levick JR, Mason RM. Changes in glycosaminoglycan concentration and synovial permeability at raised intra-articular pressure in rabbit knees. J Physiol 1996;495(Pt 3):821-33.
26. Carette S, Moffet H, Tardif J, Bessette L, Morin F, Fremont P, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829-38.
27. Buchbinder R, Youd JM, Green S, Stein A, Forbes A, Harris A, et al. Efficacy and cost-effectiveness of physiotherapy following glenohumeral joint distension for adhesive capsulitis: a randomized trial. Arthritis Rheum 2007;57:1027-37.
28. Roy JS, MacDermid JC, Woodhouse LJ. Measuring shoulder function: a systematic review of four questionnaires. Arthritis Rheum 2009;61:623-32.
29. Leidenius M, Leppänen E, Krogerus L, von Smitten K. Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg 2003;185:127-30.
30. Senkus-Konefka E, Jassem J. Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) 2006;18:229-35.
31. Lee CH, Chung SY, Kim WY, Yang SN. Effect of breast cancer surgery on chest tightness and upper limb dys-function. Medicine (Baltimore) 2019;98:e15524.